

PCT/EP99/03451

## Patent claims

- SUB A3*
1. Use of an oligoribo- or oligodeoxyribonucleotide which is capable of hybridizing with the mRNA which codes for the protein Ki-67, or of a physiologically acceptable salt thereof, for the preparation of a medicament for destroying proliferating cells.
  2. Use according to claim 1, characterized in that the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complementary to SEQ ID NO 1.
  3. Use according to claim 2, characterized in that the nucleotide sequence of the oligoribo- or oligodeoxyribonucleotide is complementary to the section from position 197 to 9962 of SEQ ID NO 1.
  4. Use according to anyone of claims 1 to 3, characterized in that the oligoribo- or oligodeoxyribonucleotide contains 12 to 66 nucleotides.
  5. Use according to anyone of claims 1 to 4, characterized in that the oligoribo- or oligodeoxyribonucleotide contains 17 to 46 nucleotides.
  6. Use according to anyone of claims 1 to 5, characterized in that the oligoribo- or oligodeoxyribonucleotide has the sequence (5'-ACC AGG CGT CTC GTG GGC CAC AT).
  7. Use according to anyone of claims 1 to 6, characterized in that one or more phosphate groups of the oligoribo- or oligodeoxyribonucleotide are replaced by phosphothioate, methylphosphonate, phosphoramidate, methylene(methylimino) and/or guanidine group(s).

- 2 -

SUB A3 8. Use according to anyone of claims 1 to 7, characterized in that the oligoribo- or oligodeoxyribonucleotide has a terminal 3'-3' and/or 5'-5' internucleotide linkage.

SUB B 9. Medicament, characterized by a content of an oligoribo- and/or oligodeoxyribonucleotide which is capable of hybridizing with the mRNA which codes for the cell cycle-associated protein Ki-67, or of a physiologically acceptable salt thereof, in addition to conventional carrier substances, auxiliaries and/or additives, wherein the amount of oligonucleotide is adjusted such that an administration of 0.001 to 100 mg/kg of body weight is achieved.

SUB A 10. Use according to anyone of claims 1 to 8 for treatment of tumours, autoimmune diseases, cicatrization, inflammations, allergies, rheumatic diseases and rejection reactions following transplantations.

11. Process for the preparation of a medicament for destroying proliferating cells, characterized by the use of oligoribo- or oligodeoxyribonucleotides which are capable of hybridizing with the mRNA which codes for the protein Ki-67, or of a physiologically acceptable salt thereof.

12. Process according to claim 11 for the preparation of a medicament for treatment of tumours, autoimmune diseases, cicatrization, inflammations, allergies, rheumatic diseases or rejection reactions following transplantations.

13. Process according to claim 11 or 12, comprising combining of an oligoribo- or oligodeoxyribonucleotide which is capable of hybridizing with the mRNA which codes for the protein Ki-67 with conventional carrier substances, auxiliaries and/or additives.

- 3 -

14. Oligoribo- or oligodeoxyribonucleotide, characterized in that it is capable of hybridizing with the mRNA which codes for the protein Ki-67, and that it contains 22 to 46 nucleotides, or a physiologically acceptable salt thereof.
15. Oligoribo- or oligodeoxyribonucleotide according to claim 14, characterized in that it contains the sequence (5' -ACC AGG TGA GCC GAG GAC GCC AT).